Step 1 of 2
These downloadable slides examine the evolving role of HER2- and TROP-2–directed antibody–drug conjugates (ADCs) in the personalized management of non-small-cell lung cancer (NSCLC). Findings from the DESTINY-Lung, TROPION-Lung, OptiTROP-Lung, and EVOKE clinical trials provide insights into the efficacy, safety, and evolving roles of approved and investigational ADCs, including trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan, and sacituzumab tirumotecan, in the treatment of NSCLC. The slides highlight the clinical implications of HER2 mutations and overexpression, EGFR mutation status, and emerging TROP-2 biomarkers for treatment selection and sequencing, as well as considerations related to prior therapy, CNS metastases, and evolving HER2-targeted treatment options. Evidence-based strategies for preventing, recognizing, and managing ADC-associated toxicities, including interstitial lung disease/pneumonitis, stomatitis, ocular toxicity, and nausea and vomiting, are also addressed, emphasizing multidisciplinary care coordination, individualized risk–benefit assessment, and clinical trial referral to optimize patient outcomes.